Clinical trials: Normal Population
Atopic Dermatitis
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product…
- Trial name
- NCT02896101
- Testing
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream
- Where
- 27 sites in United States
- Volunteers
- 755 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Acne Vulgaris
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02566369
- Testing
- CD5789 (trifarotene) 50μg/g cream
- Where
- 124 sites in United States, Canada and 3 more
- Volunteers
- 1,208 people
- Sponsor
- Galderma R&D
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Anesthesia, General
Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)
The purpose of this study is to compare the efficacy and pharmacokinetics of Org 25969 in subjects with normal or impaired renal function and to evaluate the safety of Org 25969 in subjects with impaired renal function.
- Trial name
- NCT00482599
- Testing
- Sugammadex
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratosis
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.05% to Picato gel, 0.05% and to establish the superiority of the efficacy of these two products over the…
- Trial name
- NCT02654769
- Testing
- Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
- Where
- 22 sites in United States
- Volunteers
- 441 people
- Sponsor
- Actavis Inc.
Neuroendocrine Tumours
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth…
- Trial name
- NCT00326469
- Testing
- lanreotide (Autogel formulation)
- Where
- 27 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Ipsen
Arthritis, Rheumatoid
Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)
To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.
- Trial name
- NCT00542022
- Testing
- MK0812 / Duration of Treatment: 12 Weeks
- Volunteers
- 149 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with…
- Trial name
- NCT01689532
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 17 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Janssen Pharmaceutical K.K.
Keratosis, Actinic
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm^2) and up to 100 cm^2 in adult…
- Trial name
- TirbAKare (NCT06135415)
- Testing
- Tirbanibulin, Vehicle ointment
- Where
- 35 sites in Germany, Italy and 3 more
- Volunteers
- 280 people
- Sponsor
- Almirall, S.A.
Rheumatoid Arthritis
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen…
- Trial name
- NCT01285310
- Testing
- Apremilast 30 mg, Apremilast 20 mg
- Where
- 50 sites in United States, Czechia and 2 more
- Volunteers
- 237 people
- Sponsor
- Amgen
Clonal Mast Cell Disease, KIT D816V Mutation
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
- Conditions
- Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
- Trial name
- POLARIS (NCT07143669)
- Testing
- Screening
- Where
- 26 sites in United States, Belgium
- Volunteers
- 750 people
- Sponsor
- Blueprint Medicines Corporation
Dermatitis, Allergic Contact
CP-481,715 Nickel Allergy Study.
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
- Trial name
- NCT00141180
- Testing
- CP-481,715
- Where
- 5 sites in United States, Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acne Vulgaris
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
- Trial name
- NCT02411942
- Testing
- Adapalene Gel 0.3%, Differin®
- Volunteers
- 753 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Rheumatoid Arthritis
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative and more sensitive modalities for measuring the beneficial effects of syk inhibition with fostamatinib in patients with active RA.
- Trial name
- OSKIRA 4 SS (NCT02092961)
- Testing
- Fostamatinib, Adalimumab
- Where
- 21 sites in United States, Bulgaria and 9 more
- Volunteers
- 198 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Safety Study of Abatacept in Rheumatoid Arthritis Participants
A observational study to assess whether biologic disease-modifying (BDM) treatment initiation with abatacept for rheumatoid arthritis is associated with an increased risk of serious infection and cancer
- Trial name
- NCT03696173
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 5,800 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
The purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (RA) for fostamatinib compared to placebo or adalimumab in patients who are Disease-Modifying anti-rheumatic drug (DMARD)…
- Trial name
- OSKIRA -4 (NCT01264770)
- Where
- 105 sites in United States, Bulgaria and 11 more
- Volunteers
- 644 people
- Sponsor
- AstraZeneca
Psoriasis
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
The study objectives are the following: 1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of moderate-to-severe chronic plaque-type psoriasis. 2.
- Trial name
- NCT02173301
- Testing
- XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID
- Where
- 31 sites in United States
- Volunteers
- 200 people
- Sponsor
- Dr. Reddy's Laboratories Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.